Top Markets
#1 Black Phoenix Black Phoenix +829.59%
#2 pipedog pipedog +41.28%
#3 PondCoin PondCoin +35.42%
#4 Bless Bless +35.40%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +28.74%
#6 SAFEcoin SAFEcoin +26.00%
#7 Beam Beam +24.62%
#8 Seeker Seeker +21.01%
#9 Magma Finance Magma Finance +20.64%
#10 YFSX YFSX +16.15%
Coin of the day
Black Phoenix Black Phoenix
設定
言語
日本
通貨
USD
テーマ
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
株式のランク #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
株価
$64.97
最終同期: 2024-05-20
時価総額
$1.97B
変化（1日）
0.00%
変化（1年）
0.00%
国
US
取引 Alpine Immune Sciences, Inc. (ALPN)

カテゴリー

Healthcare
Alpine Immune Sciences, Inc.（ALPN）の収益
Mar 2024 時点の収益 TTM: $56.52M
Alpine Immune Sciences, Inc. の最新の財務報告によると、現在の収益 (TTM) は $56.52M です。2022 年には $30.06M の収益があり、これは 2021 年の $23.44M と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Alpine Immune Sciences, Inc. の収益履歴（2012 ～ 2026）
各年末の収益
年 収益 変化
2026 (TTM) $56.52M -4.00%
2023 $58.88M 95.84%
2022 $30.06M 28.24%
2021 $23.44M 151.13%
2020 $9.34M 436.49%
2019 $1.74M 146.81%
2018 $705.00K -59.27%
2017 $1.73M -41.32%
2016 $2.95M 499.59%
2015 $492.00K 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 22,235.59%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 10,553.19%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 27,755.71%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 3,841.90%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH